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Changes in lymphocyte phenotype and increased skin allograft survival after
FTY720+FK506 therapy
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The development of new drugs to be associated with calcineurin inhibitors and promote
additional immunosuppression with fewer side effects is the goal in transplantation.
FTY720 is a new synthetic compound which presents immunomodulatory properties
which are not fully understood. It has been reported that the main mechanism of action
of FTY720 is to reduce the peripheral lymphocyte count by redirecting these cells toward
secondary lymphoid organs. Skin allograft transplantation in a fully mismatched strain
combination was used to investigate the potential of FTY720 alone or in combination
with a calcineurin inhibitor - FK506 - in preventing rejection. The number and phenotype
of immune system cells was also evaluated. FTY720 alone or in combination with
FK506 provided significant skin allograft survival. FTY720+FK506 therapy was
associated with decreases of total lymphocyte numbers in spleen and blood, and increases
in apoptosis levels in splenocytes. In FTY720 isolated treatment, a significant decrease
in the CD4 expression and significantly lower expressions of MHC II and ICAM-1
molecules were observed in spleen lymphocytes. Despite of allograft survival being the
same in both FTY720 and FTY720+FK506 treated groups, the association of drugs
was associated with the absence of macroscopic skin necrosis for a longer period than
the other treatments (FTY720, FK506) and histology showed less cell infiltration. Our
results suggest that a decrease of effector T cells due to elevated levels of apoptosis and
impairment in the appearance of antigens were events associated with FTY720+FK506
administration. Rev. bras. hematol. hemoter. 2008;30(3):181-187.
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E  H E M O T E R A P I A
Introduction
Improvement in immunosuppressive therapy is needed
because rejection, infection, and drug toxicity remain to be
the most common causes of morbidity and mortality in
transplantation. Drugs with potential immunomodulatory/
immunosuppressive capabilities are associated with side
effects or metabolism changes when administered for long
periods. FTY720 is a synthetic compound analog to Isaria
sinclaiiri extract that shows beneficial effects in experimen-
tal autoimmune diseases, tumor growth and metastasis,
transplantation and ischemia-reperfusion injury.1-6  FTY720
binds to the same receptor of endogenous sphingosine-1
phosphate (S1P) and causes changes in lymphocyte
trafficking by redirecting these cells to lymph nodes (LN)
and Peyer's patches (PP) preventing therefore their migration
to inflammatory sites.7
In the immune system, the major sources of S1P are
mast cells, platelets and some types of  mononuclear
phagocytes. Sphingosine 1-phosphate (S1P) regulates
diverse biological functions of many cell types, from
proliferation and survival to migration and secretion.8-10
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S1P and FTY720 are recognized with high-affinity by a
family of G-protein-coupled receptors. These receptors
transduce signals following S1P/FTY720 binding by
associating with one or more G proteins allowing a broad
range of possible downstream targets.11,12
S1P receptors (S1P
1-5
) expressed in T cells, B cells,





and low levels of S1P
3
. S1P main activity seems to be the
regulation of lymphocyte trafficking and distribution in
lymphoid tissues through binding to S1P
1
.8 The profile of
S1P-receptor expression is similar for CD4+ and CD8+ T-cell
subsets and for CD4+CD25+ regulatory T cells.13,14 In vitro
concentrations of S1P between 10 and 100 nM protected T
cells from apoptosis by inhibition of caspases, and
supported the effective function of both cytotoxic T
lymphocytes and CD4+CD25+ regulatory T cells by increased
generation of IL-10 and expression of cytotoxic T-lymphocyte
antigen 4.15
FTY720 causes decrease at blood lymphocytes and
slight increase of these cells in LN and PP after 6 to 24
hours of treatment.7,16 Lymphopenia was associated with
increased skin allograft survival after FTY720 therapy even
in mice (aly/aly) that not present secondary lymphoid organs
such as lymph nodes and Peyers' patches.17 Morris et al.
showed that FTY720 administered daily to wild C57BL/6
mice caused a sustained decrease in blood and spleen
lymphocytes whereas the accumulation of these cells in
lymph nodes was transient.18 FTY720 treatment also cau-
ses accumulation of late-stage CD4 and CD8 single positive
cells in the thymus, and intrathymic FITC labeling
experiments confirmed that this accumulation is due to a
block in thymic egress.19,20 Furthermore, FTY720 inhibits
egress of activated T lymphocytes from LNs that are
draining a site of immunization.21 Lymphopenia and the
egress-blocking activities of FTY720 most likely explains
many of its immunosuppressive effects, preventing effector
cells from reaching transplanted tissue or sites that would
normally be targeted by reactive cells. The prolonged
exposure to FTY720 generates transient lymphocyte S1P1
downregulation and inactivation22,23 and in turn the egress
of these cells from thymus and secondary lymphoid organs
is blocked.
We recently showed synergy when FTY720 and
Cyclosporine were associated with  increase at skin allograft
survival and without nephrotoxicity.24 However, it has been
shown that some patients might not be submitted to CsA
continuous administration due to toxicity and/or other side
effects. In such cases, FK506 is a candidate for CsA
substitution due its immunosuppressive potential. Therefore,
it was our aim to investigate whether FTY720 in association
with another calcineurin inhibitor (FK506) used in
transplantation could prevent skin rejection in a fully
mismatched strain combination and the possible changes
caused in immune system.
Material and Method
Eight to 10-week-old male BALB/c (H-2d, donor) and
C57BL/6 (H-2b, recipient) mice were used (bred in a local
colony) for the skin transplantation model. They received a
standard mice diet and water ad libitum. Animals were cared
for in accordance with the Principles of Laboratory Animal
Care (NIH publication No 86-23, revised 1985) and the
regulations of the Brazilian Committee on Animal.
The drugs were administered daily for 21 days starting
3 days before skin allograft transplantation. FTY720 (Novartis,
Basel, Switzerland, 1mg/kg/day diluted in sterile distilled
water) and/or FK506 (Fujisawa, Japan, 2 mg/kg/day diluted
in sterile distilled water) were administered by gavage.
Donors and recipients were anesthetized with an
intraperitoneal injection of Xylazine (Agribrands, Brazil) and
Ketamine (Vetbrands, Brazil) diluted in 10 mL of sterile PBS
(phosphate buffered solution-OXOID LTD Hampshire
England). BALB/c mice had the tail skin removed and placed
in cold saline. Tail skin was segmented in 1x1 cm2 pieces
and used to replace the previously removed back skin from
C57BL/6 mouse. The skin graft was fixed with 4-0 sutures at
each corner and animals were placed in individual cages for
daily observation. Mice were observed daily to establish
the rejection time (<90% of skin necrosis) in a set of
experiments and evaluated five days after transplantation
for changes in immune system in a second set of
experiments.
The peak of immune response is believed to occur five
days after transplantation in allograft experimental models.25
Therefore five days after skin transplantation mice were
anesthetized as described before and placed on a temperature
controlled surgical table (Braile Biomédica, Brazil) with the
purpose of opening the abdomen for blood collection and
spleen harvesting. Blood samples were used for a smear test,
whereas in spleen cell numbers and phenotype were
determined.
Blood (10 µL) collected from the vena cava was dropped
toward one end of a slide and with a cover slip it was smeared
back over the slide. A Panotico kit (Laborclin, Paraná, Brazil)
was used for staining and leukocytes were identified and
counted at microscopy.
For the examination of cell numbers in the spleen, single
cell suspension was prepared by pressing it through a 400
µm sterile nylon mesh. Single cell suspension from spleen
was submitted to 1 minute of distilled water with the aim of
causing hemolysis. Cells from spleen were counted in a
Neubauer chamber with the aid of a microscope.
Flow cytometry
1x106 cells from spleen single cell suspension were
incubated with rat anti-mouse (BD Biosciences Pharmingen)
CD4 Gam-FITC, CD54 PE (ICAM-1), I-Ab PE (MHC class II),
or Annexin-V FITC (apoptosis) for surface marker staining.26
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Cells were washed with FACS buffer (PBS/
2% FCS) and evaluated in FACScalibur
Flow Cytometer (BD Biosciences) using
Cell Sorter software. The cell population
was classified for size (forward scatter)
and complexity (side scatter) with a gate
set in the lymphocyte population. At least
10.000 cells were evaluated.
Histology
Skin sections were stained with
hematoxylin and eosin (H&E). Possible
structure changes and cell infiltration were
evaluated by a pathologist blinded to
treatment arm. Infiltration score was
defined as 0 (absence), 1 (mild), 2
(moderate) and 3 (intense).
Statistical analysis
Data are shown as mean ± standard
deviation. Kaplan-Meier analysis was
used for skin allograft survival and
comparisons among groups were
performed by analysis of variance
(ANOVA) followed by Tukey post-test for
the other parameters evaluated, except for
cell infiltration in transplanted skin where
Mood Median Test was used. The level
of statistical significance was defined as
p-value <0.05.
Results
All treatments promoted significant
skin allograft survival (Figure 1) when
compared to non-treated mice. However,
FTY720 alone or in association (FTY720
+ FK506) showed more efficacy in delaying skin allograft
survival in a fully mismatched strain combination.
Table 1 shows that in all groups C57BL/6 recipient mice
presented similar numbers of lymphocyte in the draining
(axillary) lymph node. On the other hand, a significant
decrease was observed in spleen and blood compartments
when animals were treated with  FTY720 + FK506. In blood,
the same decreased number of lymphocytes was observed in
FTY720 treated mice. FK506 single therapy was associated
with an increase of lymphocyte numbers both in spleen and
blood. CD4+ expression was lower in all treated groups when
compared with Tx non-treated mice. However, this decrease
was higher in the FTY720 Group.
FTY720 monotherapy caused a significant decrease at
MHC II and ICAM-1 (activation markers) expression in
splenocytes. For these same markers, FTY720+FK506 did not
cause the same decrease as FTY720 but percentages where
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lower in the former when compared with FK506 treatment
alone as shown in Table 2.
Lymphocyte apoptosis was significantly higher in
FTY720+FK506 Group in comparison with the other groups
Figure 1. Increased skin allograft survival in a fully mismatched strain combination after
treatment with FTY720 or FTY720+FK506. Median survival time (MST) in each mice group
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Figure 2.FTY720+FK506 treatment delays skin allograft rejection process in C57BL/6 mice transplanted with a fully mismatched strain
combination (BALB/c). Evaluation of skin necrosis percentage. A = 10% (Day+13) ; B = 20% (Day+14); C = 50% (Day+15); D = 90% (Day+16)
A B C D
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Figure 3. FTY720+FK506 treatment impaired but did not prevent cell infiltration in allogeneic transplanted skin. A.Tx-non treated (40x H&E
day+5 post transplant), B.detail of cell infiltration (200x H&E); C. FTY720+FK506 (40x H&E day +5 post transplant), D.detail of cell infiltration
(200x H&E). Median of cell infiltration in all groups compared by Mood Median test
A B
C D
Groups Tx-non treated FTY720 FK506 FTY720+FK506 p-value
Median of 2.0±0.5 2.0±1.0 2.0±1.5 2.0±1.5 0.40
cell infiltration  (n=5) (n=5) (n=5) (n=5)
while non-treated mice presented the lowest percentage of
apoptosis (Table 2).
In Figure 2 it is possible to observe that in FTY720
+FK506 group the transplanted skin is highly preserved and
the first tissue necrosis signs appear only 10 days after
transplantation. However, this treatment was not capable to
prevent cell infiltration and histology in FTY720+FK506
treated mice was only slightly different from Tx non-treated




Prevention of the rejection process without causing
toxicity is a goal in transplantation. Therefore, new drugs
have been developed with the aim that in association with
lower doses of calcineurin inhibitors (CNIs) they would cau-
se an additional immunosuppression with fewer side effects.
We recently showed in mice that the administration for 21
days of FTY720 in association with FK506 protected kidney
from histology changes and impaired the increase of glycemia
caused by FK506 single therapy.27 However, there is no report
of the immunosuppressive effect of FTY720+FK506 in
delaying skin allograft survival in a fully mismatched strain
combination. It has been shown that FTY720+CsA improve
skin allograft survival in a fully mismatched strain combination
without causing important changes in kidney function and
structure.24 These results suggest that FTY720 can be
associated to CNIs at least for a short period of time without
causing enhanced kidney side effects.
In this study, both FTY720 alone or in association with
FK506 promoted a significant increase at skin allograft
survival in a fully mismatched strain combination (BALB/c-
C57BL/6). In absence of treatment, skin was rejected in 9
days whereas with the drug combination the maximum of
allograft survival obtained was 16 days. FK506 single therapy
caused a less important increase of skin allograft survival
when compared with FTY720 and FTY720+FK506 treated
groups.
In despite of the good results observed in experimental
models using FTY720 its  mechanism of action is not fully
understood. In agreement with previous reports,19,28 our
results showed that FTY720 causes decrease at blood
lymphocytes. The same was observed when FTY720 was
associated with FK506. Also in  agreement with our data,
Morris et al. showed that FTY720 administered daily to
C57BL/6 mice caused a sustained decrease in blood and
spleen lymphocytes whereas the accumulation of these cells
in lymph nodes was transient. We found similar lymphocyte
numbers in lymph nodes of all  groups five days after skin
allograft transplantation (nine days of FTY720 daily
administration). Morris et al. observed that after ten days of
FTY720 daily administration there was a return of T cells to
the initial values in peripheral lymph nodes.18 FTY720+FK506
Group presented a decreased number of lymphocytes at
spleen site suggesting that immunosuppression was based
on lack of cells to cause rejection. It has been reported that
FTY720 acts mostly in blood lymphocytes and has a major
effect in CD4+ T cells.19,28 Our results showed that FTY720
alone or in combination with FK506 caused a more important
decrease in splenic CD4+ T cells when compared with FK506
single therapy or non-treated groups.
Activation markers involved in antigen presentation
(MHC II) and immune cells migration and adhesion (ICAM-
1) where slightly decreased in spleen cells from FTY720 and
FTY720+FK506 treated mice when compared with FK506 alone.
However, this decrease was more important in FTY720 treated
group. A significant decrease at MHC class I and class II
expression was observed in murine peritoneal macrophages
stimulated with IFN-γ in vitro when FTY720 was added as
reported by Hwang et al.29 suggesting that FTY720 acts not
only in T cells but also in antigen presenting cells (APC). In
agreement with Hwang data, our results suggest that besides
the decrease in lymphocytes capable to promote rejection,
antigen presentation and effector cell migration to the
inflammatory site (graft) is prevented or delayed by FTY720.
Taking into account that MHC-deficient mice present a delay
in skin allograft rejection when compared with wild type
animals30 it could be argued that FTY720 therapy caused
improvement in skin allograft survival in our experiments,
among other mechanisms, by preventing MHC II expression
in APCs.
Apoptosis levels increased in all treated groups in
comparison with Tx non-treated mice but FTY720+FK506
caused the higher apoptosis levels in splenocytes. This
finding could explain the decreased number of lymphocytes
in spleen and blood obtained in the group treated with
FTY720+FK506.
Ten days after transplantation there was a  preserved
macroscopic view of the skin graft in FTY720+FK506 whereas
the Tx non-treated Group had already rejected the graft.
However, our findings in skin histology showed that the
infiltration score in FTY720+FK506 Group was only slightly
lower that in Tx non-treated Group. Infiltrating cells in all
groups were mainly lymphocytes and neutrophils. In opposite
to our findings some authors have found that FTY720 impairs
T cell infiltration in the allograft. Yanagawa et al.31 showed
that skin transplant in non-treated MHC-incompatible rat
strains causes a higher amount of infiltrating CD8+ T cells
when compared with CD4+ T cells five days after
transplantation. CD8+ T cells infiltration was not prevented
by FTY720 but there was a significant decrease of this cell
phenotype in comparison with non-treated rats. FTY720 has
been shown to have more effects on CD4+ T cells than in
CD8+ T cells and that the later cell subtype is sufficient to
mediate allorecognition and graft rejection even in absence
of T cell helper.32 Wang et al.33 showed that FTY720 cause
cardiac allograft rescue from ongoing rejection and was
associated with decrease in blood lymphocytes and increase
of these cells in peripheral lymph nodes. Mononuclear cells
infiltration was not prevented by FTY720 treatment but the
presence of these cells was not as high as in non-treated
group. Hwang et al.29 showed that in murine cardiac
transplantation 10 mg/kg/day of FTY720 was associated with
strong suppression of acute rejection in comparison with
CsA (40 mg/kg/day). CsA group presented histological
findings such as coronary vasculitis with intraluminal
accumulation of mononuclear leukocytes which were
attenuated by FTY720 treatment. It could also be argued that
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our histology findings five days post transplantation were
associated with tissue damage rather than with rejection
process. Yet, pro-inflammatory cells and their products might
be necessary to maintain the graft micro-environment balan-
ce which guarantees tissue acceptance or rejection delay.
In conclusion, FTY720 alone or in association with
FK506 showed efficacy in delaying skin allograft rejection
mainly due to apoptosis causing decrease of lymphocyte
numbers in periphery and impairment in the expression of
activation markers by these cells. Our results show that
FTY720 might be associated to subtherapeutic levels of FK506
causing marked prolongation of skin allograft survival when
compared with FK506 monotherapy. The major implications
for this finding are the possibility of drugs synergistic
combinations, reduced doses of immunosuppressive drugs
and in turn less side effects.
Resumo
O objetivo na área dos transplantes é o desenvolvimento de novas
drogas que possam ser associadas a inibidores da calcineurina
para evitar o processo de rejeição e causar menos efeitos colaterais.
FTY720 é um novo composto sintético que apresenta propriedades
imunomoduladoras não completamente elucidadas. Foi relatado
que o principal mecanismo de ação do FTY720 é a redução do
número de linfócitos periféricos através do redirecionamento des-
sas células para órgãos linfóides secundários. O alotransplante de
pele entre linhagens de camundongos completamente incompatí-
veis quanto ao MHC foi usado para investigar o potencial de FTY720
isolado ou em combinação com um inibidor da calcineurina - FK506
- na prevenção da rejeição. Também foram avaliados o número e
fenótipo das células do sistema imune. A administração de FTY720
como monoterapia ou FTY720+FK506 associou-se a uma diminui-
ção do número total de linfócitos no baço e no sangue e aumento
dos níveis de apoptose nos esplenócitos. No grupo tratado somente
com FTY720, foi observada uma diminuição mais importante da
expressão de CD4 e expressão significativamente menor de molé-
culas de MHC II e ICAM-1. Apesar de a sobrevida do aloenxerto
ter sido igual para os grupos tratados com FTY720 ou FTY720
+FK506, a associação das drogas promoveu ausência de necrose
macroscópica da pele por um período maior do que os outros
tratamentos (FTY720, FK506) e os achados histológicos mostra-
ram menor infiltrado celular. Nossos resultados sugerem que uma
diminuição do número de células T efetoras devido a elevados
níveis de apoptose e o prejuízo da apresentação de antígenos foram
os eventos associados à administração de FTY720+FK506. Rev.
bras. hematol. hemoter. 2008; 30(3):181-187.
Palavras-chave: Camundongo; alotransplante de pele; rejeição;
imunossupressão; citometria de fluxo.
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